ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trospium chloride

Also written as “Xanomeline/trospium chloride”, “Xanomeline/Trospium Chloride Capsule” and “Xanomeline/Trospium Chloride”.

Its studies are mostly in Schizophrenia · Urinary Bladder, Overactive · Alzheimer Disease · Mania · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageTrospium chloride: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 13, 202515 company-led studies, 7 open or runningNext primary completion: Dec 3, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb97 open or runningphase 4since Oct 13, 2025Jul 6, 2016Dec 3, 2026phase 1 · NCT07204418
AbbVieits history only50 open or runningphase 4since Mar 16, 2009Mar 16, 2009none ahead
Keenova Therapeuticsits history only10 open or runningphase 2since Apr 24, 2007Apr 24, 2007none ahead

Also a collaborator on its studies: Alkermes.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2016First study: phase 1 study in SchizophreniaFirst studyNCT02831231 · 70 enrolled · United States
  2. Jun 2, 20252 phase 3 studies in Alzheimer DiseaseNCT07011745, NCT07011732
  3. Jun 23, 2025Phase 1 study in Healthy VolunteersNCT07063342 · 236 planned · United Kingdom
  4. Aug 21, 2025Phase 3 study in ManiaNCT07140913 · 424 planned · United States, Argentina, Bulgaria and more
  5. Sep 24, 2025Phase 1 study in Healthy VolunteersNCT07204418 · 56 planned · United States
  6. Oct 13, 2025Phase 4 study in SchizophreniaNCT07221877 · 60 planned · United States
  7. Nov 21, 2025Phase 4 study in Healthy VolunteersNCT07257120 · 10 enrolled · United States
  8. Jun 30, 2026Phase 3 study in SchizophreniaNCT07686263 · 472 planned · United States, Argentina, Bulgaria and more

Ahead

  1. Dec 3, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07204418
  2. Mar 29, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07063342
  3. Jun 28, 2027Primary completion: phase 3 study in ManiaNCT07140913
  4. Dec 30, 2027Primary completion: phase 4 study in SchizophreniaNCT07221877

TargetBeta

CHRM2 →CHRM3 →read by rule
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
trospiumruleBristol-Myers Squibbphase 421
AtropineruleLaboratorios Sophia S.A de C.V.phase 317

Studies

All 9 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07686263Schizophrenia · United States, Argentina, Bulgaria and more3RecruitingMar 3, 2029472
NCT07257120Healthy Volunteers · United States4CompletedJun 8, 202610
NCT07221877Schizophrenia · United States4RecruitingDec 30, 202760
NCT07204418Healthy Volunteers · United States1RecruitingDec 3, 202656
NCT07140913Mania · United States, Argentina, Bulgaria and more3RecruitingJun 28, 2027424
NCT07063342Healthy Volunteers · United Kingdom1RecruitingMar 29, 2027236
NCT07011745Alzheimer Disease · United States, Argentina, Chile and more3RecruitingNov 3, 2028426
NCT07011732Alzheimer Disease · United States, Argentina, Brazil and more3RecruitingNov 24, 2028426
NCT02831231Schizophrenia · United States1CompletedOct 28, 201670

How it is read

Names in the registry

  • “Xanomeline/trospium chloride”, 2 entries
  • “Xanomeline/Trospium Chloride Capsule”, 2 entries
  • “Xanomeline/Trospium Chloride”, 2 entries
  • “Trospium Chloride”, 2 entries
  • “trospium chloride”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.